Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Conditions:   Cirrhosis;   Cirrhosis, Liver;   Cirrhosis Early;   Cirrhosis Due to Hepatitis B;   Cirrhosis Advanced;   Cirrhosis Infectious;   Cirrhosis Alcoholic;   Cirrhosis, Biliary;   Cirrhosis Cryptogenic;   Cirrhosis Due to Hepatitis C;   Cirrhosis Due to Primary Sclerosing  Cholangitis Intervention:   Drug: Rosuvastatin Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   The Cleveland Clinic;   Columbia University;   Weill Medical College of Cornell University;   Duke University;   Mayo Clinic;   University of Miami;   University of Michigan;   University of Calif ornia, San Diego;   University of California, San Francisco;   LAC+USC Medical Center;   Virginia Commonwealth University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   National Cancer Institute (NCI);   University of Southern California Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials